- Home
- SXTP vs ENTO Comparison
SXTP vs ENTO Comparison
Compare SXTP & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- ENTO
- Stock Information
- Founded
- SXTP 2010
- ENTO 2014
- Country
- SXTP United States
- ENTO United States
- Employees
- SXTP N/A
- ENTO N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- ENTO Health Care
- Exchange
- SXTP Nasdaq
- ENTO Nasdaq
- Market Cap
- SXTP 2.4M
- ENTO 2.9M
- IPO Year
- SXTP 2023
- ENTO 2016
- Fundamental
- Price
- SXTP $0.45
- ENTO $0.49
- Analyst Decision
- SXTP Hold
- ENTO
- Analyst Count
- SXTP 1
- ENTO 0
- Target Price
- SXTP N/A
- ENTO N/A
- AVG Volume (30 Days)
- SXTP 5.8M
- ENTO 68.7K
- Earning Date
- SXTP 03-31-2025
- ENTO 11-13-2024
- Dividend Yield
- SXTP N/A
- ENTO N/A
- EPS Growth
- SXTP N/A
- ENTO N/A
- EPS
- SXTP N/A
- ENTO N/A
- Revenue
- SXTP $462,612.00
- ENTO N/A
- Revenue This Year
- SXTP $141.35
- ENTO N/A
- Revenue Next Year
- SXTP $175.16
- ENTO N/A
- P/E Ratio
- SXTP N/A
- ENTO N/A
- Revenue Growth
- SXTP 128.99
- ENTO N/A
- 52 Week Low
- SXTP $0.41
- ENTO $0.19
- 52 Week High
- SXTP $7.20
- ENTO $9.35
- Technical
- Relative Strength Index (RSI)
- SXTP 33.01
- ENTO 43.83
- Support Level
- SXTP $0.47
- ENTO $0.45
- Resistance Level
- SXTP $0.67
- ENTO $0.54
- Average True Range (ATR)
- SXTP 0.10
- ENTO 0.06
- MACD
- SXTP 0.00
- ENTO 0.00
- Stochastic Oscillator
- SXTP 12.96
- ENTO 24.31
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.